{
    "id": 641,
    "fullName": "ERBB3 A232V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) A232V lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org, PMID: 23680147). A232V confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147).",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "A232V",
    "createDate": "06/04/2014",
    "updateDate": "04/30/2015",
    "referenceTranscriptCoordinates": {
        "id": 123458,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56087876C>T",
        "cDna": "c.695C>T",
        "protein": "p.A232V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 745,
                "profileName": "ERBB3 A232V"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) A232V (PMID: 23680147).",
            "molecularProfile": {
                "id": 745,
                "profileName": "ERBB3 A232V"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11946,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 745,
                "profileName": "ERBB3 A232V"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) A232V in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 745,
                "profileName": "ERBB3 A232V"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 745,
            "profileName": "ERBB3 A232V",
            "profileTreatmentApproaches": [
                {
                    "id": 14784,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 A232V"
                },
                {
                    "id": 14780,
                    "name": "Trastuzumab",
                    "profileName": "ERBB3 A232V"
                },
                {
                    "id": 14782,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 A232V"
                },
                {
                    "id": 14781,
                    "name": "Pertuzumab",
                    "profileName": "ERBB3 A232V"
                },
                {
                    "id": 14783,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 A232V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123458,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56087876C>T",
            "cDna": "c.695C>T",
            "protein": "p.A232V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}